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Increased understanding of the genetic aetiology of advanced non-small-cell lung cancer (aNSCLC) has facilitated
personalised therapies that target specific molecular aberrations associated with the disease. Biopsy samples for
mutation testing may be taken from primary or metastatic sites, depending on which sample is most accessible,
and upon differing diagnostic practices between territories. However, the mutation status concordance between
primary tumours and corresponding metastases is the subject of debate. This review aims to ascertain whether
molecular diagnostic testing of either the primary or metastatic tumours is equally suitable to determine patient
eligibility for targeted therapies. A literature search was performed to identify articles reporting studies of mutations
in matched primary and metastatic aNSCLC tumour samples. Clinical results of mutation status concordance
between matched primary and metastatic tumour samples from patients with aNSCLC were collated. Articles
included in this review (N =26) all reported mutation status data from matched primary and metastatic tumour
samples obtained from adult patients with aNSCLC. Generally, substantial concordance was observed between
primary and metastatic tumours in terms of EGFR, KRAS, BRAF, p16 and p53 mutations. However, some level of
discordance was seen in most studies; mutation testing methodologies appeared to play a key role in this, along
with underlying tumour heterogeneity. Substantial concordance in mutation status observed between primary and
metastatic tumour sites suggests that diagnostic testing of either tumour type may be suitable to determine a
patient’s eligibility for personalised therapies. As with all diagnostic testing, highly sensitive and appropriately
validated mutation analysis methodologies are desirable to ensure accuracy. Additional work is also required to
define how much discordance is clinically significant given natural tumour heterogeneity. The ability of both
primary and metastatic tumour sites to accurately reflect the tumour mutation status will allow more patients to
receive therapies personalised to their disease.
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Lung cancer is the leading cause of cancer mortality [1],
with non-small-cell lung cancer (NSCLC) accounting
for ~85 % of primary lung cancers [2]. Metastatic
spread of the disease is a complication of advanced
NSCLC (aNSCLC) [3], which usually precedes the fatal
stages by a few months. Unfortunately, many patients
present with metastases at diagnosis [4] due to the rela-
tively asymptomatic earlier stages of the disease.
Increased understanding of the genetic aetiology of
aNSCLC over the past decade has provided the oppor-
tunity for personalised treatment for some patients,
targeting several of the key molecular aberrations now
known to be associated with aNSCLC [5, 6]. A recent
meta-analysis of the incidence and coincidence of muta-
tions in aNSCLC reported that three genes – tumour
protein p53 (TP53), epidermal growth factor receptor
(EGFR) and v-Ki-ras2 Kirsten rat sarcoma viral onco-
genes homolog (KRAS) – were commonly mutated in
NSCLC of adenocarcinoma (ADC) histology [7], one of
the most common histological subtypes of NSCLC
[2, 8]. The functional pathways associated with these
genes are well-documented [9–11], however in brief:
mutations in EGFR are known to activate the MAPK/
ERK pathway [10, 11]; mutations in KRAS, BRAF and
PIK3CA are known to alter MAPK/ERK activation [10,
11]; and mutations in TP53 are known to lead to loss of
function of this tumor suppressor [9].
Molecular diagnostic testing is now recommended by
several clinical guidelines [12–14] for patients with
NSCLC to determine eligibility for targeted therapies.
For example, EGFR tyrosine kinase inhibitors (TKIs),
such as gefitinib and erlotinib, are approved for patients
with mutations in the EGFR gene; it is now widely ac-
cepted that response to EGFR TKIs is greater in patients
with tumours harbouring EGFR mutations compared
with wild-type EGFR oncogenes [15]. Similarly, translo-
cations involving the anaplastic lymphoma kinase gene
predict patients who will respond to the TKI crizotinib
[16]. Further to this, new targeted therapies are being
developed for patients with other molecular aberrations;
for example, selumetinib, cobimetinib and trametinib are
being developed for patients with KRAS mutation-
positive tumours [17].
As a result of the availability of targeted therapies, de-
termining tumour mutation status in patients with
aNSCLC is now a key component of diagnosis in many
countries, with the hope, where possible, of optimising
treatment outcomes [18, 19]. Currently, most aNSCLC
cases are diagnosed by a histological analysis of the
tumour tissue; for example, around 77 % of patients in
England and Wales (UK) are diagnosed in this manner
[20]. However, depending on patient ability and/or will-
ingness to undergo sampling, whether samples areavailable or evaluable, and differing diagnostic practices
between countries [12, 13, 21–25], either the primary
tumour or a metastatic lesion may be biopsied [26].
However, the concordance in mutation status between
matched primary and metastatic tumours is the subject
of debate [3, 27–33], with limited understanding as to
whether discordance reflects actual heterogeneity in mu-
tations, or is an artifact of technical/sensitivity limita-
tions in testing methodology [34–43]. Nevertheless,
given that the collection of multiple invasive samples
from a patient with NSCLC is undesirable, it is import-
ant to ascertain whether the mutation status of an indi-
vidual patient’s NSCLC can be accurately characterised
from biopsies of either the primary or metastatic sites.
Although research into the concordance of EGFR and
KRAS mutation status between matched primary and
metastatic tumours exists [33], to the authors’ know-
ledge, no review to date has systematically assessed the
currently available data regarding whether metastatic
samples are representative of primary tumour samples in
patients with aNSCLC in terms of multiple mutations,
and included consideration of the mutation testing
methodologies employed. To address this knowledge
gap, we describe in this review the level of mutation sta-
tus concordance between matched primary and meta-
static tumour samples, considering EGFR, KRAS and
any other molecular aberrations noted in the included




Literature searches of the MEDLINE® and PubMed®
databases were carried out to identify journal articles
published before 8 September 2014, which reported
studies of mutations in aNSCLC tumour samples of pri-
mary or metastatic origin. The following search criteria
were used: [NSCLC OR Lung] AND [mutation] AND
[Primary] AND [Metas*]. The following were ex-
cluded: [non-English papers] AND [Editorials] AND
[Commentaries]. Case reports, reviews and meta-analyses
were also excluded, due to the variability in mutation test-
ing methodologies used, which would limit the conclusions
that could be drawn from such studies.
Articles were reviewed to identify those reporting re-
sults of clinical studies of mutation status concordance
between matched primary and metastatic tumour sam-
ples from patients with aNSCLC. Where possible, the
following parameters were recorded: study population
demographics (age, gender, ethnicity and smoking sta-
tus); number of matched tumour samples; description of
matched tumour samples; molecular marker assessed;
molecular marker assessment technique; mutation fre-
quency in primary compared with metastatic tumour
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primary and metastatic tumour samples. Gene expres-
sion data, where reported, were not included.
Results
Included studies
The literature search yielded 370 relevant abstracts, of
which 26 were considered relevant for inclusion based
upon the fact that they reported mutation data (any
gene) for both primary and corresponding metastatic
samples from patients with aNSCLC (Fig. 1). One study
included data from small-cell lung cancers [44], and
another included data from paired synchronous double
tumours [45]; the remaining 24 studies are listed in
Tables 1, 2, 3 and 4.
Patient demographics
Key demographic data, where available/applicable, are
presented in Tables 1, 2, 3 and 4.
EGFR mutation status concordance
In total, 14 reports of EGFR mutation status concord-
ance between matched primary and metastatic tumours
were identified, of which four were in Caucasian pa-
tients: Kalikaki et al. [46] (Table 3) analysed 25 primary
tumours and corresponding lung (n = 9), thoracic wall
(n = 5), adrenal gland (n = 4), brain (n = 3), bone (n = 2),
skin (n = 1) and liver (n = 1) metastases, and determined
the EGFR mutation status concordance to be 72 %
(18/25). Schmid et al. [47] (Table 3) analysed 96 pri-
mary tumours and corresponding lymph node metas-
tases of Austrian patients, and found EGFR mutation
status concordance to be 94 % (90/96). In a US study,
Munfus-McCray et al. [48] (Table 3) assessed 9 primaryFig. 1 Study selection flow diagram. Literature searches carried out on 25tumours and corresponding metastatic tumours of the
brain (n = 3), lymph node (n = 3) or pleura/knee/lung
(n = 1 each), and found EGFR mutation status concord-
ance to be 89 % (8/9). Lastly, Mansuet-Lupo et al. [30]
(Table 1) analysed 10 primary tumours and correspond-
ing lymph node (n = 8) or pleural metastases (n = 2) of
French patients, and found EGFR mutation status con-
cordance to be 90 % (9/10); the discordant result was
obtained from a metastatic lymph node containing <15 %
tumour cells, and an EGFR mutation corresponding to
the primary tumour was subsequently identified in an-
other lymph node from this patient, resulting in 100 %
concordance.
Other studies of lymph node metastases, a commonly
assessed metastatic site, were in Asian patients. Sun
et al. [32] (Table 3) analysed 80 primary tumours and
corresponding lymph node metastases of Chinese pa-
tients, and found EGFR mutation status concordance to
be 91 % (73/80). Two of the discordant cases resulted
from a different EGFR mutation being present in the pri-
mary versus metastatic tumour (E746-A750 vs L747-
T751 and L747-P753insS vs R748-P752, respectively). In
two more recent studies of Chinese patients, Han et al.
[49] (Table 3) and Wei et al. [50] (Table 1) analysed, re-
spectively, 22 and 50 primary tumours and correspond-
ing lymph node metastases, and found EGFR mutation
status concordance to be 95 % (21/22) and 94 % (47/50).
However, quantitative analysis in Wei et al’s study indi-
cated that EGFR mutation ratios (amount of mutant
EGFR:all EGFR present) were significantly lower in
metastatic compared with primary tumour samples
(Wilcoxon matched-pair test; P < 0.01), suggesting a
more moderate mutation ratio concordance of 84 %. In
two studies of Japanese patients, Yatabe et al. [51]July 2013, 3 January 2014 and 8 September 2014
Table 1 Summary of studies reporting assessment of EGFR molecular marker





















Assessment of EGFR molecular marker
Chen et al. [27] (i) 58 (27–84) 180 Archived Lung Lymph node: 49 40:140 High-resolution
melting method

















Pleural: 8 31/41 (76)
Brain: 5 [Paired primary lung
tumours and distant
metastases]
Liver: 3 30/35 (86)










Gow et al. [28] (i) 61 (38–80) 67 FFPE Lung Brain: 25 N/A Direct sequencing
and ARMS method
[Direct sequencing] [Direct sequencing]




9.3 months (range: 0–90)
































Luo et al. [54] (i) 55 (26–79) at diagnosis 15 FFPE Lung Brain N/A ARMS method 7/15 (47) vs 8/15 (53) 14/15 (93)








(i) N/A 10 FFPE Lung Lymph node: 8 N/A ‘Locally validated
tests’
N/A 10/10 (100)









6/8 (75) vs 6/8 (75) 8/8 (100)









Park et al. [31] (i) 61 (32–82) 101 FFPE Lung Lymph node 101:0 Direct sequencing
and heteroduplex
analysis
[Direct sequencing] [Direct sequencing]
(ii) 73/101 (72.3) [Concurrent] 21/101 (21) vs
11/101 (11)
89/101 (88)

















(ii) 46/70 (66) ADC: 35 [Concurrent]






























(ii) N/A ADC: 9 N/A
(iii) [USA]
(iv) N/A
Wei et al. [50] (i) [38/50 > 60 years;
12/50≤ 60 years]





(ii) 11/50 (N/A) ADC: 49 N/A











ADC Adenocarcinoma, ADQCC Adenosquamous carcinoma, ARMS Amplification‐refractory mutation system, EGFR Epidermal growth factor receptor, FFPE Formalin-fixed paraffin-embedded, LCC Large cell carcinoma,
N/A Not available, PCR Polymerase chain reaction, PNA-LNA Peptide nucleic acid-locked nucleic acid, SSC Squamous cell carcinoma
aAs described in study (country from which samples were taken from)
bConcurrent or non-concurrent if time not specified
cPrimary vs metastatic tumour samples














Table 2 Summary of studies reporting assessment of KRAS molecular marker






















Assessment of KRAS molecular marker
Alsdorf et al. [55] (i) N/A 19 FFPE Lung Lymph node N/A ARMS method with
direct sequencing
after enrichment
of tumour cells by
laser capture
microdissection




Badalian et al. [57] (i) N/A (47–76) 11 FFPE Lung Bone N/A RFLP-PCR 3/11 (27) vs 3/11 (27) 7/11 (64)
(ii) 8/11 (72.7) N/A
(iii) [Hungary]
(iv) N/A
Cortot et al. [3] (i) [Mean] 59.7 (39–73) 21 FFPE Lung Brain: 13 6:15 Direct sequencing
and mutant-enriched
PCR
[Direct sequencing] [Direct sequencing]
(ii) 6/21 (28.6) ADC: 16 Lung: 4 N/A 3/21 (14) vs 4/21 (19) 15/21 (71)
(iii) [France] SSC: 2 Bone: 2 [Mutant-enriched PCR]
(iv) N/A LCC: 2 Soft tissue: 2 17/21 (81)








6/10 (60) vs 6/10 (60) 10/10 (100)
(ii) Male:female ratio, 1:1 N/A
(iii) [USA]
(iv) 70 % of patients















Table 2 Summary of studies reporting assessment of KRAS molecular marker (Continued)
Li et al. [56] (i) 60 (36–80) 15 FFPE Lung Various N/A Oligodeoxy-nucleotide
hybridisation of DNA
amplified by PCR




(ii) 13/15 (87) ADC: 6 [Concurrent]
(iii) [Spain] SSC: 4




ADC Adenocarcinoma, ARMS Amplification‐refractory mutation system, DNA Deoxyribonucleic acid, FFPE Formalin-fixed paraffin-embedded, KRAS Kirsten rat sarcoma viral oncogenes homolog, LCC Large cell carcinoma,
N/A Not available, PCR Polymerase chain reaction, RFLP-PCR Restriction fragment length polymorphism-polymerase chain reaction, SSC Squamous cell carcinoma
aAs described in study (country from which samples were taken from)
bConcurrent or non-concurrent if time not specified














Table 3 Summary of studies reporting assessment of EGFR/KRAS or EGFR/KRAS/other molecular markers























Assessment of EGFR/KRAS molecular markers
Han et al. [49] (i) 60 (44–76) 22 Snap frozen Lung Lymph node N/A Direct sequencing [EGFR] [EGFR]
(ii) 12/22 (55) ADC: 15 N/A 7/22 (32) vs 6/22 (27) 21/22 (95)






2/22 (9) vs 1/22 (5) 21/22 (95)
Han et al. [29] (i) 66 (40–94) 37 FFPE Lung Pleural effusion: 12 32:5 Direct sequencing [EGFR] [EGFR]
(ii) 20/37 (54.1) ADC: 37 Pleura: 9 N/A 18/37 (49) vs 16/37 (43) 30/37 (81)












Kalikaki et al. [46] (i) 55 (41–70) 25 FFPE Lung Lung: 9 0:25 Direct sequencing [EGFR] [EGFR]






5/25 (20) vs 3/25 (12) 18/25 (72)
(iii) Caucasian SSC: 2 Adrenal gland: 4 [KRAS] [KRAS]
(iv) Never-smoker:
3/25 (12); active or
former smoker:
22/25 (88)
ADC/BAC: 2 Brain: 3 5/25 (20) vs 5/25 (20) 19/25 (76)
LCC: 2 Bone: 2















Table 3 Summary of studies reporting assessment of EGFR/KRAS or EGFR/KRAS/other molecular markers (Continued)
Munfus-McCray
et al. [48]
(i) 56.3 (51–80) 9 FFPE Lung Brain: 3 N/A [EGFR] Bidirectional
DNA sequencing
[EGFR] [EGFR]
(ii) N/A (66.7) Lymph node: 3 N/A [KRAS] Pyrosequencing
following microdissection
of tumour tissue
3/9 (33) vs 2/9 (22) 8/9 (89)
(iii) [USA] Pleura: 1 [KRAS] [KRAS]
(iv) Never-smoker: 4/9
(N/A); current and
former smoker: 4/9 (N/A)
Knee: 1 1/9 (11) vs 2/9 (22) 8/9 (89)
Contralateral lung: 1
Sun et al. [32] (i) [Mean] 58 (32–77) 80 FFPE Lung Lymph nodes 80:0 Direct sequencing [EGFR] [EGFR]
(ii) 50/80 (62.5) ADC: 39 [Concurrent] 21/80 (26) vs 26/80 (33) 73/80 (91)







1/80 (1) vs 7/80 (9) 74/80 (93)
LCC: 4
Assessment of EGFR/KRAS/BRAF molecular markers





(ii) 58/96 (60.4) N/A 4/96 (4) vs 4/96 (4) 90/96 (94)











Assessment of EGFR/KRAS/p53 molecular markers
Takahashi et al. [61] (i) [At diagnosis]
(43–79)












3/8 (38) vs 3/8 (38)
(iii) [Japan] SSC: 1 Liver: 2 [p53]
(iv) Never-smoker: 3;
ever-smoker: 5
LCC: 1 Pulmonary: 1 7/8 (88) vs 7/8 (88)
SCC: 3 Pleural: 1 [KRAS]
0/8 (0) vs 0/8 (0)
ADC Adenocarcinoma, BAC Bronchioloalveolar carcinoma, BRAF Murine sarcoma viral oncogene homolog B1, DNA Deoxyribonucleic acid, EGFR Epidermal growth factor receptor, FFPE Formalin-fixed paraffin-embedded,
GCC Giant cell carcinoma, KRAS Kirsten rat sarcoma viral oncogenes homolog, LCC Large cell carcinoma, N/A Not available, SCC Small cell carcinoma, SNP Single nucleotide polymorphism, SSC Squamous cell carcinoma
aAs described in study (country from which samples were taken from)
bConcurrent or non-concurrent if time not specified














Table 4 Summary of studies reporting assessment of ‘other’ (non-EGFR/KRAS) molecular markers























Assessment of p16 molecular marker
Marchetti et al. [59] (i) [Mean] 60 (36–76) 30 FFPE Lung Lymph node N/A Direct sequencing
by PCR-SSCP




Assessment of somatic alterations
Vignot et al. [62] (i) N/A (41–82) 15 Frozen Lung Locoregional: 7 2:13 Targeted next-genera n
sequencing assay
[EGFR] [Somatic mutations]
(ii) N/A (13/15) ADC: 8 CNS: 3 N/A 1/32 (3) vs 1/31 (3) N/A (94)








Parietal: 1 4/32 (13) vs 4/31 (13)
[NOTCH1]
1/32 (3) vs 1/31 (3)
[PIK3CA]
4/32 (13) vs 3/31 (10)
[RB1]
1/32 (3) vs 1/31 (3)
[SMARCA4]
1/32 (3) vs 1/31 (3)
[STK11]















Table 4 Summary of studies reporting assessment of ‘other’ (non-EGFR/KRAS) molecular markers (Continued)
[TP53]
12/32 (41) vs 12/31 (42)
[Large structural
alterations]
5/32 (16) vs 5/31 (16)
ADC Adenocarcinoma, CNS Central nervous system, EGFR Epidermal growth factor receptor, FFPE Formalin-fixed paraffin-embedded, KRAS Kirsten rat sarcoma viral oncogenes homolog, LCC Large cell carcinoma,
N/A Not available, PCR-SSCP Polymerase chain reaction-single-strand conformation polymorphism, SSC Squamous cell carcinoma
aAs described in study (country from which samples were taken from)
bConcurrent or non-concurrent if time not specified
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respectively, 77 and 70 primary tumours and corre-
sponding lymph node metastases, and found EGFR mu-
tation status concordance to be 100 % (77/77) and 86 %
(60/70). Park et al. [31] (Table 1) analysed 101 primary
tumours and corresponding lymph node metastases of
Korean patients. EGFR mutation status concordance was
found to be 88 % (89/101) via direct sequencing, with 11
discordant cases EGFR mutation-positive in the primary
tumour only and one discordant case EGFR mutation-
positive in the metastatic tumour only; however, retesting
with a more sensitive heteroduplex analysis decreased the
concordance to 83 % (84/101).
Another commonly studied metastatic site was the
brain. Matsumoto et al. [53] (Table 1) analysed 8 pri-
mary tumours and corresponding brain metastases of
Japanese patients, with an EGFR mutation status con-
cordance of 100 % (8/8) detected via direct sequencing.
Luo et al. [54] (Table 1) implemented the amplification-
refractory mutation system (ARMS) method in their
retrospective study of EGFR mutations in 15 primary tu-
mours and corresponding brain metastases obtained
from Chinese patients, which yielded a concordance of
93 % (14/15).
Other studies included additional metastatic sites as
well as the brain. Gow et al. [28] (Table 1) analysed 67
primary tumours and corresponding metastases of the
following sites obtained from Taiwanese patients: brain
(n = 25); bone (n = 20); and pleura/skin/soft tissue, dis-
tant lymph node, gastrointestinal system, metastatic
lung tumour or adrenal gland (n = 22). EGFR mutation
status concordance was found to be 61 % (41/67) via
direct sequencing. The 26 discordant results were
EGFR mutation-positive in their metastatic tumour
only; these were reanalysed using the ARMS method,
which indicated that 10/26 (38 %) of these were in fact
concordant. Combining the ARMS and direct se-
quencing results yielded an overall concordance of
73 % (49/67). Han et al. [29] (Table 3) analysed 37
primary tumours and corresponding metastases of
the following sites obtained from Korean patients: pleural
effusion (n = 12), pleura (n = 9), brain (n = 5), lymph node
(n = 3), lung (n = 2), soft tissue (n = 2), adrenal gland
(n = 1), pericardial effusion (n = 1), pericardium (n = 1) and
ovary (n = 1); EGFR mutation status concordance was
found to be 81 % (30/37).
KRAS mutation status concordance
Overall, 10 reports of KRAS mutation status concord-
ance between matched primary and metastatic tumours
were identified, of which three analysed lymph node
metastases. Schmid et al. [47] (Table 3, previously
described) found KRAS mutation status concordance to
be 74 % (71/96), including one discordant result of aKRAS mutation that was different in the primary (G12C)
versus the metastatic (G12R) tumour, and another with
unknown mutation status in the corresponding primary
tumour of a KRAS mutation-positive metastasis. Un-
usually, two patients with an EGFR mutation (one with
the mutation in their primary tumour and one with the
mutation in a lymph node metastasis) had an additional
KRAS mutation in the corresponding metastases. Sun
et al. [32] (Table 3, previously described) found a KRAS
mutation status concordance of 93 % (74/80). Alsdorf
et al. [55] (Table 2) analysed 19 primary tumours and
corresponding lymph node metastases of German patients.
Direct sequencing yielded 4 discordant results; however,
re-evaluation of mutation status using a combination of
the ARMS method and enrichment of tumour cells by
laser capture microdissection found identical KRAS muta-
tions in all 19 matched pairs (100 % concordance).
Other studies assessed mixed/non-lymph node meta-
static sites, mostly in Caucasian patients apart from Han
et al’s study [29] in Korean patients (Table 3, previously
described), which found a KRAS mutation status con-
cordance of 97 % (36/37).
The remaining studies were as follows: Li et al. [56]
(Table 2) analysed 15 primary tumours and corresponding
metastases of various origin obtained from Spanish pa-
tients (with multiple sites tested per patient), and found a
KRAS mutation status concordance rate of 100 % (15/15).
A retrospective study by Badalian et al. [57] (Table 2)
analysed 11 primary tumours and corresponding bone
metastases of Hungarian patients using a restriction frag-
ment length polymorphism-polymerase chain reaction
(RFLP-PCR) method, and found a KRAS mutation status
concordance of 64 % (7/11). Another retrospective study
by Kalikaki et al. [46] (Table 3, previously described)
found KRAS mutation status concordance to be 76 %
(19/25). Cortot et al. [3] (Table 2) analysed 21 primary
tumours and corresponding metachronous/synchronous
metastases of the brain (n = 13), lung (n = 4) or bone/soft
tissue (n = 2 each), obtained from French patients. Direct
sequencing found KRAS mutation status concordance to
be 71 % (15/21); however, re-testing using a mutant-
enriched PCR analysis increased the concordance to
81 % (17/21). In a study of US patients, Holst et al. [58]
(Table 2) analysed 10 primary tumours and correspond-
ing intrathoracic metastases of patients with the bronchi-
oloalveolar adenocarcinoma NSCLC subtype, and found
a KRAS mutation status concordance of 100 % (10/10).
In a further study of US patients, Munfus-McCray et al.
[48] (Table 3, previously described) found a KRAS muta-
tion status concordance of 89 % (8/9).
Concordance of other mutations
In total, four studies included analysis of other muta-
tions as well as/instead of those in KRAS and EGFR.
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tions in 26 primary lung tumours and 60 corresponding
metastases obtained from Swiss patients. A total of 7/9
patients with p53 mutation in the primary tumour had
identical mutations in all corresponding metastases. In
one patient with discordant results, a p53 mutation was
found in one metastatic site (liver), but wild-type p53
was detected in the primary tumour and in a metastatic
lesion of the kidney. In the other patient, a p53 mutation
was detected in the primary tumour and one metastatic
site (kidney), whereas wild-type p53 was detected in a
metastatic lesion of the liver. Further to this, Holst et al.
[58] (Table 2, previously described) found that when p53
loss of heterozygosity was detected in the primary tumour,
it was also detected in the corresponding metastases.
An Italian study by Marchetti et al. [59] (Table 4)
assessed 30 primary tumours and corresponding lymph
node metastases, and found a p16 mutation status con-
cordance of 100 % (30/30).
Schmid et al. [47] (Table 3, previously described) ob-
served novel BRAF exon 15 mutations in 2 primary tu-
mours and not in corresponding metastases in Austrian
patients. However, KRAS/BRAF and EGFR/BRAF muta-
tions were found to be mutually exclusive.
Allelic patterns between primary and metastatic tumours
Two studies included in this review presented results
related to EGFR mutation heterogeneity in matched pri-
mary and metastatic tumour samples.Fig. 2 EGFR mutation pattern in 56 primary tumour and 30 lymph node m
adenocarcinomas. A homogeneous mutation pattern was detected in five
metastasis case. Case 6 had mixed wild-type and mutant sites in both prim
growth factor receptor. Reprinted from Cancer Prev Res (Phila), 2008, 1, 192
the pathogenesis and progression of lung adenocarcinomas, with permissiTang et al. [60] (Table 1) assessed EGFR mutation het-
erogeneity in primary tumours and corresponding lymph
node metastases from 9 EGFR mutation-positive pa-
tients, by taking multiple samples from non-contiguous
sites of both primary tumours and metastases. Overall,
54/56 (96 %) and 25/30 (83 %) primary and metastatic
tumour sites were EGFR mutation-positive, respectively.
A total of 5/9 patients had identical EGFR mutations at
multiple sites within the primary tumour and corre-
sponding metastases; however, 2/9 patients presented
with two different variants of Exon 19 deletions within
the primary tumour: 1/9 patients had a mixture of wild-
type EGFR and EGFR Exon 19 deletions; and 1/9
patients carried both L858R mutations and Exon 19 de-
letions. However, metastases were non-heterogeneous,
with only a single type of mutation detected in each
which was always present in at least one site of the pri-
mary tumour (Fig. 2).
Further to this, Takahashi et al. [61] (Table 3) com-
pared whole-genome allelic imbalance of 8 primary
tumours and corresponding brain (n = 7), lymph node
(n = 3), liver (n = 2), pulmonary (n = 1) and pleural (n = 1)
metastases obtained from Japanese patients. p53 and EGFR
mutations were detected in 7/8 (88 %) and 3/8 (38 %) pri-
mary tumours and corresponding metastases, respectively.
Genetic alterations were similar between the majority of
cases (>67 %); however, there were genetic alterations
(specifically, chromosomal regions of allelic imbalance
indicated by imbalance of allele homo-/heterozygosity)etastasis sites obtained from nine patients with EGFR-mutant lung
primary tumours (cases 2, 3, 4, 7 and 9) and all but one (case 6)
ary tumour sites and corresponding metastases. EGFR, epidermal
–200, Tang et al., Epidermal growth factor receptor abnormalities in
on from AACR [60]
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in the primary but not metastatic tumour in 4/8 cases.
Mutation patterns in multiple primary tumours
Two papers included in our review included analysis of
mutation status concordance between multiple primary
tumours.
A Japanese study by Matsuzoe et al. [45] investigated
p53 mutations in 20 paired synchronous double tu-
mours; p53 mutations occurred in 7/20 samples, with
three different distributions: (i) only one tumour had the
mutation (4/7); (ii) each tumour had a different muta-
tion (2/7); and (iii) the same mutation was found in both
tumours (1/7). In addition, 3/7 patients had metastatic
lymph nodes in which p53 mutations were found that
were identical to those found in the corresponding pri-
mary tumour. The third pattern (iii) was suggested to
represent metastatic lung cancer.
Chen et al. [27] (Table 1) analysed 180 primary tumours
and corresponding metastases of Asian patients. They
found the following concordance rates for EGFR muta-
tions: paired pulmonary primary nodules, 76 % (31/41);
paired primary lung tumours and distant metastases, 86 %
(30/35); paired primary lung tumours and metastatic
lymph nodes, 90 % (44/49); and paired metachronous
primary tumours (i.e. diagnosed at different times), 91 %
(50/55). Overall concordance was estimated at 86 %
(155/180) using a high-resolution melting method.
Somatic versus passenger mutations
Most studies included in this review were restricted to
analysis of a small set of biomarkers. Interestingly, a
French study by Vignot et al. [62] (Table 4) investigated
the presence of multiple somatic alterations in 15 pri-
mary tumours and corresponding metastases (locoregio-
nal [n = 73], central nervous system [n = 3], distant
adenopathy [n = 2], adrenal [n = 1], cutaneous [n = 1],
parietal [n = 1]) and determined which alterations were
likely to be driving recurrent mutations (defined as mu-
tations that occur in ≥5 % of NSCLC samples in the
Catalogue of Somatic Mutations in Cancer or are
amplified/deleted in ≥5 % of NSCLC samples in the
literature) or passenger mutations (all other mutations).
A total of 161 and 190 somatic alterations were identified
in the primary and metastatic tumours, respectively. Of
these, 159 of these were classed as likely to be passenger
mutations; the concordance rate between mutations
found in primary compared with metastatic tumours was
94 % for recurrent mutations and 63 % for those consid-
ered likely to be passenger mutations.
Discussion
This literature review aimed to describe the level of
mutation status concordance between primary andcorresponding metastatic tumours, considering EGFR,
KRAS and any other molecular aberrations noted. Vari-
ous factors could contribute to mutation status discord-
ance, such as differences in the sensitivity of mutation
testing methods [63], mutation heterogeneity within the
samples themselves [60, 61], or evolution of the muta-
tion status of the primary and metastatic tumours [61].
Understanding these factors is important to learn how
mutation testing may be improved, in order to ensure
that as many patients as possible can access therapies
personalised to the mutation status of their NSCLC
tumours.
Most studies in this review focussed on EGFR and
KRAS mutations, and in general, substantial mutation
status concordance was found in terms of both. Further-
more, there was limited evidence to suggest, as other
studies have [64], that KRAS mutation status concord-
ance was lower than EGFR mutation status concordance
in studies that analysed both mutations [29, 32, 46, 48, 49].
EGFR mutation frequency was found to be higher than
KRAS mutation frequency in most [29, 48, 49, 61], but not
all [46, 47], studies. A minority of studies included analysis
of other molecular aberrations (BRAF, p53 and p16); re-
sults of these also indicated substantial mutation status
concordance.
Where reported, discordance appeared to be partly re-
lated to the mutation testing methodology utilised. Many
studies used direct sequencing to assess mutation status,
which is known to be relatively insensitive [65], with
mutations needing to be present in around 20 % of al-
leles interrogated [42, 43] to avoid false-negative results
[33]. Retesting and confirmation of mutation results with
more sensitive techniques was commonly employed by
studies in this review. Park et al. [31] found EGFR muta-
tion concordance was 83 % upon retesting with hetero-
duplex analysis versus 88 % with direct sequencing; 8
EGFR mutations were detected by heteroduplex analysis
that were not picked up by direct sequencing, indicating
the presence of false negatives. Similarly, the ARMS
methodology was employed by some studies, which in-
creased the concordance rates found by direct sequen-
cing [28, 55].
The number of neoplastic versus non-neoplastic cells
in tumour samples can also affect detection of mutations
[66]. For example, Mansuet-Lupo et al. [30] detected an
EGFR mutation in all metastatic lymph node samples of
a patient aside from one sample which contained just
15 % tumour cells. Most studies included in this review
used samples with >30 % tumour cells, and some
employed laser-capture microdissection [67] to enrich
tumour cell content in their samples [53, 55, 61].
Another methodological limitation of most studies in
this review was the use of formalin-fixed paraffin-
embedded (FFPE) tumour tissues; DNA breakages can
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linked to false-negative or -positive results. Other sample
types may be more appropriate for mutation testing, in-
cluding fresh/archived cytologic samples [69] and blood
serum/plasma samples [26, 70] (not included in this
review). There are data that have shown EGFR concord-
ance rates are higher when analysing archival smear
slides compared with FFPE tissues; Sun et al. [4] com-
pared primary tumour FFPE histological material with
fresh-frozen metastatic material, and found a higher rate
of mutation in the fresh samples. In addition to this, a
relatively large direct sequencing PCR amplicon was
used (292 base pairs), which could have resulted in a
much decreased sensitivity in fragmented FFPE-derived
material compared with fresh-frozen tissue.
Another potential cause of mutation status discord-
ance was the site of the metastatic sample; only one
study included in our review specifically included muta-
tion analysis comparing primary lung tumours and both
corresponding lymph node and distant metastases [27],
which yielded concordance rates of 90 and 86 %, re-
spectively. This study also compared discordance rates
between metachronous and synchronous tumours,
which were 16 and 8 %, respectively. There was a lack of
similar data from other studies, with most not reporting
whether primary and metastatic samples were taken
simultaneously.
However, although mutation test methodologies con-
tribute to discordance, natural intratumoural heterogen-
eity cannot be excluded as a factor, which was observed
in some studies in this review. For example, two studies
investigated allelic patterns in tumours [60, 61], and
found differences in heterozygosity and mutation sub-
type between primary tumours and their corresponding
metastases. When Takahashi et al. [61] investigated the
nature of each case where different genetic alterations
were observed between matched primary and metastatic
tumours, the process of metastasis was found to vary,
suggesting multiple models of tumour progression and
metastatic origins may apply in lung cancer; larger stud-
ies are needed to investigate this further. It is also inter-
esting to note the findings of the study by Vignot et al.
[62], who found that the global level of discordance could
at least be partly attributed to passenger mutations.
Although not the focus of this review, limited data
were found regarding the association between clinico-
pathological characteristics and mutation status con-
cordance. Where data were available, as with previous
studies, EGFR mutations were associated with female
sex [32], non-smoker status [32, 47] and ADC histology
[32]; one study found KRAS was associated with current
smokers [47].
EGFR mutations in both primary and metastatic tu-
mours were also found to be linked to response to EGFRTKI therapy. For example, Shimizu et al. [52] found the
disease control rate to be significantly higher in patients
with EGFR mutation-positive primary and metastatic tu-
mours versus patients with EGFR mutation-positive pri-
mary tumours only (P = 0.062). Furthermore, Kalikaki
et al. [46] found that of two patients who developed
metachronous metastasis following EGFR TKI therapy,
one had acquired resistance to the TKI therapy due to a
metastatic tumour with a T790M EGFR mutation. The
T790M EGFR mutation is one of the most common
mechanisms leading to resistance to TKI therapy, of
which there are several [71]. This suggests that consider-
ation of alterations in EGFR mutation status during
tumour progression is important, and repeat mutation
testing may, therefore, be appropriate during clinical
management of patients.
Most, but not all, studies included in this review re-
ported that where both primary and corresponding
metastatic tumours were EGFR mutation-positive prior
to any therapy, the same mutation subtype was ob-
served. However, further work is needed to determine
the impact of both TKI therapies and chemotherapies on
the mutation status of both primary and metastatic
tumours (including the emergence of new mutation
subtypes), and the resulting need for repeat biopsy.
Furthermore, there is a need for further data reporting
on the concordance of the presentation of other bio-
markers between primary and metastatic tumours; for
example, although mutation expression profiles were be-
yond the scope of this review, there are ongoing and im-
portant developments in personalised therapies targeting
proteins differentially expressed in tumours [72].
This review is limited by the heterogeneous patient
populations included in the studies, with sample size,
patient demographics, disease characteristics, tumour
sampling methods and treatment histories differing
substantially, and not always reported. This review was
also limited to English papers only. Furthermore, until
optimum testing techniques have been further researched
and defined, the effects of the different mutation testing
techniques discussed in this review cannot be fully
evaluated.
Conclusions
The high level of concordance in mutation status be-
tween matched primary and metastatic tumours re-
ported in studies here suggest that both sample types are
equally viable options for informing treatment decisions
based on mutation status. Robust mutation testing must
be carried out to ensure accuracy of analysis; key com-
ponents of robust mutation testing include the sensitiv-
ity of the assay and the quality and quantity of the
tumour sample used. Furthermore, additional work is re-
quired to describe and define how much discordance is
Sherwood et al. Journal of Experimental & Clinical Cancer Research  (2015) 34:92 Page 17 of 18clinically relevant given natural tumour heterogeneity.
The opportunity, therefore, exists for patients whose pri-
mary tumours are not available and/or evaluable to re-
ceive personalised therapy following mutation analysis of
a metastatic lesion.
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